Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

1.

Autophagy and endocrine resistance in breast cancer.

Cook KL, Shajahan AN, Clarke R.

Expert Rev Anticancer Ther. 2011 Aug;11(8):1283-94. doi: 10.1586/era.11.111. Review.

PMID:
21916582
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.

Howell SJ, Johnston SR, Howell A.

Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. Review.

PMID:
14687597
[PubMed - indexed for MEDLINE]
3.

Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?

Howell A, Howell SJ, Clarke R, Anderson E.

J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):227-37. Review.

PMID:
11850229
[PubMed - indexed for MEDLINE]
4.

Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.

Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A, Giordano A, Perrone F; NCI-Naple Breast Cancer Group.

Endocr Relat Cancer. 2005 Dec;12(4):721-47. Review.

PMID:
16322319
[PubMed - indexed for MEDLINE]
Free Article
5.

Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.

Morris C, Wakeling A.

Endocr Relat Cancer. 2002 Dec;9(4):267-76. Review.

PMID:
12542403
[PubMed - indexed for MEDLINE]
Free Article
6.

Fulvestrant ('Faslodex'): current and future role in breast cancer management.

Howell A.

Crit Rev Oncol Hematol. 2006 Mar;57(3):265-73. Epub 2006 Feb 9. Review.

PMID:
16473018
[PubMed - indexed for MEDLINE]
7.

Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.

Buzdar AU.

Oncologist. 2003;8(4):335-41. Review.

PMID:
12897330
[PubMed - indexed for MEDLINE]
Free Article
8.

Life following aromatase inhibitors--where now for endocrine sequencing?

Johnston SR, Martin LA, Dowsett M.

Breast Cancer Res Treat. 2005;93 Suppl 1:S19-25. Review.

PMID:
16247596
[PubMed - indexed for MEDLINE]
9.

Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer.

Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM.

Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S29-36. Review.

PMID:
16113097
[PubMed - indexed for MEDLINE]
Free Article
10.

Targeting GRP78 and antiestrogen resistance in breast cancer.

Cook KL, Clarke PA, Clarke R.

Future Med Chem. 2013 Jun;5(9):1047-57. doi: 10.4155/fmc.13.77. Review.

PMID:
23734687
[PubMed - indexed for MEDLINE]
11.

Cannibalism, cell survival, and endocrine resistance in breast cancer.

Clarke R.

Breast Cancer Res. 2011 Aug 12;13(4):311. doi: 10.1186/bcr2870. Review.

PMID:
21884644
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Fulvestrant: a new type of estrogen receptor antagonist for the treatment of advanced breast cancer.

Buzdar AU.

Drugs Today (Barc). 2004 Sep;40(9):751-64. Review.

PMID:
15538548
[PubMed - indexed for MEDLINE]
13.

Preliminary experience with pure antiestrogens.

Howell A.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4369s-4375s; discussion 4411s-4412s. Review.

PMID:
11916227
[PubMed - indexed for MEDLINE]
14.

Endocrine treatment options for advanced breast cancer--the role of fulvestrant.

Robertson JF, Come SE, Jones SE, Beex L, Kaufmann M, Makris A, Nortier JW, Possinger K, Rutqvist LE.

Eur J Cancer. 2005 Feb;41(3):346-56. Review.

PMID:
15691633
[PubMed - indexed for MEDLINE]
15.

Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.

Jordan VC, Brodie AM.

Steroids. 2007 Jan;72(1):7-25. Epub 2006 Dec 13. Review.

PMID:
17169390
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
17.
18.

Biological characteristics of the pure antiestrogen fulvestrant: overcoming endocrine resistance.

Dowsett M, Nicholson RI, Pietras RJ.

Breast Cancer Res Treat. 2005;93 Suppl 1:S11-8. Review.

PMID:
16247595
[PubMed - indexed for MEDLINE]
19.

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.

Johnston SR, Martin LA, Head J, Smith I, Dowsett M.

J Steroid Biochem Mol Biol. 2005 May;95(1-5):173-81. Review.

PMID:
15996863
[PubMed - indexed for MEDLINE]
20.

Fulvestrant (Faslodex): current status in the therapy of breast cancer.

Bundred N, Howell A.

Expert Rev Anticancer Ther. 2002 Apr;2(2):151-60. Review.

PMID:
12113237
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk